3-methylthioxanthone-10,10-oxide | 87548-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: 3-methylthioxanthone-10,10-oxide
• 英文别名: 3-Methyl-10lambda~6~-thioxanthene-9,10,10-trione；3-methyl-10,10-dioxothioxanthen-9-one
• CAS: 87548-99-0
• 化学式: C₁₄H₁₀O₃S
• 分子量: 258.298
• InChiKey: ZUEJEJCYPTYLDY-UHFFFAOYSA-N

物化性质

• 熔点：
  158.5-160.0 °C
• 沸点：
  492.6±35.0 °C(Predicted)
• 密度：
  1.393±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(3-甲基苯基)硫烷基苯甲酸 在 硫酸 、 双氧水 作用下， 以 溶剂黄146 为溶剂， 反应 1.5h， 生成 3-methylthioxanthone-10,10-oxide
  参考文献：
  名称：

  Brindle, Ian D.; Doyle, Paul P., Canadian Journal of Chemistry, 1983, vol. 61, p. 1869 - 1871

  摘要：

  DOI：

文献信息

• Compounds for Nonsense Suppression, and Methods for Their Use
  申请人：Almstead Neil G.

  公开号：US20090253699A1

  公开（公告）日：2009-10-08

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及使用本发明的化合物或组合物治疗或预防与mRNA中无意义突变相关的疾病的方法、化合物和组合物。更具体地，本发明涉及用于抑制与mRNA中无意义突变相关的早期翻译终止的方法、化合物和组合物。
• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070142351A1

  公开（公告）日：2007-06-21

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其显示对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与需要该治疗的患者的多巴胺D3受体活性有关，包括向受试者投予所述化合物的治疗有效量以缓解该疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（如帕金森病、帕金森综合征、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合征和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律障碍和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物用作多巴胺D3受体成像剂的方法。
• Diaminopropionic acid derivatives
  申请人：Fotouhi Nader

  公开号：US20070155671A1

  公开（公告）日：2007-07-05

  A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

  化合物1a的公式，对于治疗再灌注损伤是有用的，包括盐类、前药和相关化合物。
• Synthesis of Thioxanthone 10,10-Dioxides and Sulfone-Fluoresceins via Pd-Catalyzed Sulfonylative Homocoupling
  作者：Gergely Knorr、Mariano L. Bossi、Alexey N. Butkevich、Stefan W. Hell

  DOI：10.1021/acs.orglett.3c04300

  日期：2024.2.2

  Our report describes the facile and scalable preparation of 9H-thioxanthen-9-one 10,10-dioxides via Pd-catalyzed sulfonylative homocoupling of the appropriately substituted benzophenones. This transformation provides a straightforward route to previously unreported sulfone-fluoresceins and -fluorones. Several examples of these red fluorescent dyes have been prepared, characterized, and evaluated as

  我们的报告描述了通过适当取代的二苯甲酮的 Pd 催化磺酰化自偶联来轻松且可规模化地制备 9 H-噻吨-9-酮 10,10-二氧化物。这种转化为以前未报道的砜荧光素和荧光酮提供了一条直接的途径。这些红色荧光染料的几个例子已经被制备、表征和评估为与具有 775 nm 受激发射损耗的超分辨率荧光显微镜兼容的活细胞渗透标记。
• Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
  申请人：PTC Therapeutics, Inc.

  公开号：EP2301536A1

  公开（公告）日：2011-03-30

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过施用本发明的化合物或组合物治疗或预防与 mRNA 中无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及抑制与 mRNA 中无义突变相关的过早翻译终止的方法、化合物和组合物。